Pluri (PLUR) Competitors $5.14 -0.04 (-0.68%) As of 12:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLUR vs. NKTX, CLYM, ELDN, SLN, MOLN, THTX, HURA, ALTS, CRDF, and GNLXShould you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Nkarta (NKTX), Climb Bio (CLYM), Eledon Pharmaceuticals (ELDN), Silence Therapeutics (SLN), Molecular Partners (MOLN), Theratechnologies (THTX), TuHURA Biosciences (HURA), ALT5 Sigma (ALTS), Cardiff Oncology (CRDF), and Genelux (GNLX). These companies are all part of the "pharmaceutical products" industry. Pluri vs. Its Competitors Nkarta Climb Bio Eledon Pharmaceuticals Silence Therapeutics Molecular Partners Theratechnologies TuHURA Biosciences ALT5 Sigma Cardiff Oncology Genelux Pluri (NASDAQ:PLUR) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings. Does the media favor PLUR or NKTX? In the previous week, Pluri had 1 more articles in the media than Nkarta. MarketBeat recorded 3 mentions for Pluri and 2 mentions for Nkarta. Nkarta's average media sentiment score of 1.24 beat Pluri's score of 0.63 indicating that Nkarta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pluri 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nkarta 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, PLUR or NKTX? Pluri has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Do institutionals and insiders hold more shares of PLUR or NKTX? 16.6% of Pluri shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 25.9% of Pluri shares are owned by company insiders. Comparatively, 8.4% of Nkarta shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is PLUR or NKTX more profitable? Nkarta has a net margin of 0.00% compared to Pluri's net margin of -2,563.29%. Nkarta's return on equity of -27.74% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Pluri-2,563.29% -4,191.91% -85.40% Nkarta N/A -27.74%-22.38% Which has higher earnings & valuation, PLUR or NKTX? Pluri has higher revenue and earnings than Nkarta. Nkarta is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPluri$330K122.46-$20.89M-$5.53-0.93NkartaN/AN/A-$108.79M-$1.48-1.41 Do analysts prefer PLUR or NKTX? Pluri currently has a consensus target price of $12.00, suggesting a potential upside of 133.69%. Nkarta has a consensus target price of $13.60, suggesting a potential upside of 550.72%. Given Nkarta's higher possible upside, analysts clearly believe Nkarta is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Nkarta 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryNkarta beats Pluri on 9 of the 15 factors compared between the two stocks. Get Pluri News Delivered to You Automatically Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLUR vs. The Competition Export to ExcelMetricPluriMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.41M$3.07B$5.75B$9.74BDividend YieldN/A2.26%3.95%4.03%P/E Ratio-0.9321.0631.3826.41Price / Sales122.46353.19428.94154.89Price / CashN/A44.7137.7559.42Price / Book5.148.0410.446.58Net Income-$20.89M-$53.98M$3.27B$265.92M7 Day Performance-9.60%-1.02%1.04%0.13%1 Month Performance0.69%5.50%5.72%2.07%1 Year Performance-7.48%9.31%49.36%21.31% Pluri Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLURPluri2.2184 of 5 stars$5.14-0.7%$12.00+133.7%-10.9%$40.41M$330K-0.93150Gap DownNKTXNkarta2.1321 of 5 stars$2.20-0.2%$13.60+519.6%-58.0%$155.90MN/A-1.48140CLYMClimb Bio3.3816 of 5 stars$2.30-7.3%$9.00+291.3%N/A$155.86MN/A-3.299ELDNEledon Pharmaceuticals1.7229 of 5 stars$2.60+1.0%$10.00+285.4%-9.8%$155.39MN/A-2.2210SLNSilence Therapeutics2.9642 of 5 stars$5.09+0.5%$33.83+565.4%-72.9%$152.19M$27.17M-3.08100MOLNMolecular Partners1.7585 of 5 stars$3.73-11.7%$12.00+222.1%-41.5%$150.42M$5.65M-1.94180Earnings ReportAnalyst RevisionGap DownHigh Trading VolumeTHTXTheratechnologiesN/A$3.26+0.2%N/A+152.9%$149.67M$85.87M-17.13140HURATuHURA Biosciences1.8605 of 5 stars$2.99+1.4%$12.67+323.6%N/A$149.65MN/A0.00N/AALTSALT5 Sigma0.5252 of 5 stars$6.89+1.3%N/A+259.9%$148.89M$12.53M0.00170High Trading VolumeCRDFCardiff Oncology2.1138 of 5 stars$2.21-0.2%$10.10+358.0%-9.2%$146.69M$545K-2.5320News CoverageGNLXGenelux1.8652 of 5 stars$3.83+2.4%$17.75+363.4%+78.3%$144.70M$10K-4.4510News CoveragePositive News Related Companies and Tools Related Companies Nkarta Competitors Climb Bio Competitors Eledon Pharmaceuticals Competitors Silence Therapeutics Competitors Molecular Partners Competitors Theratechnologies Competitors TuHURA Biosciences Competitors ALT5 Sigma Competitors Cardiff Oncology Competitors Genelux Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLUR) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluri Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluri With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access